3004 Methoxyflurane An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) 76-38-0 4116 C3H4Cl2F2O 163.960730 -35°C 105°C 2.83E+004 mg/L (at 37°C) Oral Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca²⁺ activated potassium channel, the glutamate receptor and the glycine receptor. Hepatic. LD50: 3600 mg/kg (Oral, Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For use in the induction and maintenance of general anesthesia Detrimental effects on the kidneys. [Wikipedia] Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage. 2009-07-21T20:28:12Z 2014-12-24T20:25:54Z Methoxyflurane C07517 384208 Methoxyflurane DB01028 true COC(F)(F)C(Cl)Cl C3H4Cl2F2O InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3 InChIKey=RFKMCNOHBTXSMU-UHFFFAOYSA-N 164.966 163.960726574 Exogenous Liquid 2.21 HMDB15162 CHEMBL1341 3973